DCF — RIVERSIDE MEDICAL CENTER
Enterprise Value: $-422.3M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-422.3M
Enterprise Value
$-138.2M
PV of Cash Flows
$-284.1M
PV of Terminal Value
$-457.6M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $400.8M | $-23.8M | -6.0% | $-40.8M | $-37.1M |
| Year 2 | $412.8M | $-20.4M | -5.0% | $-37.9M | $-31.3M |
| Year 3 | $425.2M | $-16.7M | -4.0% | $-34.7M | $-26.1M |
| Year 4 | $438.0M | $-15.1M | -3.0% | $-33.6M | $-23.0M |
| Year 5 | $451.1M | $-14.4M | -3.0% | $-33.5M | $-20.8M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-422.3M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$389.1M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.06439220394381724
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5